 |
| Bloody good news: Red Cross to switch to Apollo proteins |
The Australian Red Cross has indicated its Blood Service will start using one of Apollo Life Sciences' human-based protein products for its blood testing.
The Blood Service's Sydney Branch stated its plan to switch after comparing Apollo's IL-2 protein with one made by a major pharmaceutical company.
Red Cross uses IL-2 proteins in tests to ensure transplant donors and recipients have compatible blood types.
"Apollo compared favourably with the IL-2 we are currently using and was more sensitive at lower doses," said the Red Cross Blood Service's Dr Lyanne Weston.
"We were impressed with these results and will be very happy to use Apollo IL-2 in future work."
Apollo will now promote IL-2 and other proteins to Red Cross's other branches, with the goal of nationwide take-up.
Apollo has developed a range of 60 different proteins which are used in drug research and development, diagnostic testing, and medical treatments.
Unlike competitors' products, which are produced using E.coli bacteria, Apollo's proteins are grown in human cells.
This means they more closely mimic proteins in the human body, which can make them more accurate, more stable and more encouraging of cell growth – all considerable assets for researchers.
It is extremely difficult to produce proteins from human cells.
Apollo is the only company that has mastered this technology across a wide range of proteins.
This gives Apollo a highly competitive market position.
The global research proteins market is worth over $520 million annually.
Apollo's commercial strategy is to build its research proteins business as an early revenue source, which will fund longer-term pharmaceutical product development. |
|
|
| click to subscribe |
|
 |
| www.apollolifescience.com |
